β blockers, atrial fibrillation, and heart failure

The Lancet

Volumn 384, Issue 9961, 2014, Pages 2181-2183

  McMurray, John J V ^a   Van Veldhuisen, Dirk J ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ATRIAL FIBRILLATION; HEART FAILURE; HUMAN; MORTALITY;

ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; HEART FAILURE; HUMANS;

EID: 84919341500     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62340-0     Document Type: Note

References (12)

1. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
2. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
3. M Packer, AJS Coats, MB Fowler for the Carvedilol Prospective Randomized Cumulative Survival Study Group Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
4. JJ McMurray, S Adamopoulos, SD Anker et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 14 2012 803 869
5. CW Yancy, M Jessup, B Bozkurt et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
6. D Kotecha, J Holmes, H Krum on behalf of the Beta-Blockers in Heart Failure Collaborative Group Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient-data meta-analysis Lancet 384 2014 2235 2243
7. M Rienstra, K Damman, BA Mulder, IC Van Gelder, JJ McMurray, DJ van Veldhuisen Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis JACC Heart Fail 1 2013 21 28
8. S Yusuf, J Wittes, J Probstifield, HA Tyroler Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials JAMA 266 1991 93 98
9. T Houghton, N Freemantle, JG Cleland Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials Eur J Heart Fail 2 2000 333 340
10. AU Khand, AC Rankin, W Martin, J Taylor, I Gemmell, JG Cleland Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42 2003 1944 1951
11. D Castagno, H Skali, M Takeuchi CHARM Investigators Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program J Am Coll Cardiol 59 2012 1785 1795
12. LG Olsson, K Swedberg, A Ducharme CHARM Investigators Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program J Am Coll Cardiol 47 2006 1997 2004